(CNC) Centene - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US15135B1017
Stock: Health Insurance, Government Programs, Pharmacy, Clinical Care
Total Rating 31
Risk 73
Buy Signal -0.51
| Risk 5d forecast | |
|---|---|
| Volatility | 54.5% |
| Relative Tail Risk | -12.1% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.55 |
| Alpha | -49.36 |
| Character TTM | |
|---|---|
| Beta | 0.266 |
| Beta Downside | -0.416 |
| Drawdowns 3y | |
|---|---|
| Max DD | 68.65% |
| CAGR/Max DD | -0.26 |
EPS (Earnings per Share)
Revenue
Description: CNC Centene March 04, 2026
Centene Corporation (CNC) is a US-based managed care company. It provides healthcare programs and services to under-insured families and commercial organizations.
The company operates across four segments: Medicaid, Medicare, Commercial, and Other. The Medicaid segment, a significant component of the managed care sector, provides services including temporary assistance for needy families and childrens health insurance programs. The Medicare segment offers special needs plans and prescription drug plans. The Commercial segment focuses on individual and group health insurance marketplace products. The Other segment includes clinical healthcare, pharmacies, and vision, dental, and behavioral health services.
Centenes business model involves delivering healthcare services through a network of primary and specialty care physicians, hospitals, and other providers. Managed care organizations aim to control healthcare costs and improve outcomes for their members. For further detailed analysis, consider exploring ValueRay.
Headlines to watch out for
- Medicaid enrollment fluctuations impact revenue and profitability
- Government healthcare spending policies dictate segment growth
- Medicare Advantage plan performance drives market share
- Commercial health insurance competition pressures margins
- Regulatory changes in healthcare directly affect operations
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: -6.67b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 6.16 > 1.0 |
| NWC/Revenue: 7.45% < 20% (prev 2.29%; Δ 5.16% < -1%) |
| CFO/TA 0.07 > 3% & CFO 5.09b > Net Income -6.67b |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.68 > 1.5 & < 3 |
| Outstanding Shares: last quarter (491.1m) vs 12m ago -2.17% < -2% |
| Gross Margin: 12.24% > 18% (prev 0.10%; Δ 1.21k% > 0.5%) |
| Asset Turnover: 243.3% > 50% (prev 197.8%; Δ 45.52% > 0%) |
| Interest Coverage Ratio: -9.46 > 6 (EBITDA TTM -5.14b / Interest Expense TTM 678.0m) |
Altman Z'' 1.21
| A: 0.19 (Total Current Assets 35.99b - Total Current Liabilities 21.48b) / Total Assets 77.66b |
| B: 0.11 (Retained Earnings 8.67b / Total Assets 77.66b) |
| C: -0.08 (EBIT TTM -6.42b / Avg Total Assets 80.05b) |
| D: 0.15 (Book Value of Equity 8.62b / Total Liabilities 57.60b) |
| Altman-Z'' Score: 1.21 = BB |
Beneish M -3.38
| DSRI: 0.77 (Receivables 18.11b/19.71b, Revenue 194.78b/163.07b) |
| GMI: 0.84 (GM 12.24% / 10.32%) |
| AQI: 0.99 (AQ_t 0.51 / AQ_t-1 0.51) |
| SGI: 1.19 (Revenue 194.78b / 163.07b) |
| TATA: -0.15 (NI -6.67b - CFO 5.09b) / TA 77.66b) |
| Beneish M-Score: -3.38 (Cap -4..+1) = AA |
What is the price of CNC shares?
As of March 16, 2026, the stock is trading at USD 34.45 with a total of 6,296,671 shares traded.
Over the past week, the price has changed by -20.48%, over one month by -16.44%, over three months by -14.83% and over the past year by -41.85%.
Over the past week, the price has changed by -20.48%, over one month by -16.44%, over three months by -14.83% and over the past year by -41.85%.
Is CNC a buy, sell or hold?
Centene has received a consensus analysts rating of 3.89.
Therefore, it is recommended to buy CNC.
- StrongBuy: 7
- Buy: 3
- Hold: 9
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CNC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 44.4 | 28.9% |
| Analysts Target Price | 44.4 | 28.9% |
CNC Fundamental Data Overview March 12, 2026
P/E Forward = 12.3457
P/S = 0.1001
P/B = 0.8971
P/EG = 1.5233
Revenue TTM = 194.78b USD
EBIT TTM = -6.42b USD
EBITDA TTM = -5.14b USD
Long Term Debt = 17.35b USD (from longTermDebt, last quarter)
Short Term Debt = 196.0m USD (from shortTermDebt, last quarter)
Debt = 18.78b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 889.0m USD (from netDebt column, last quarter)
Enterprise Value = 18.52b USD (17.63b + Debt 18.78b - CCE 17.89b)
Interest Coverage Ratio = -9.46 (Ebit TTM -6.42b / Interest Expense TTM 678.0m)
EV/FCF = 4.29x (Enterprise Value 18.52b / FCF TTM 4.32b)
FCF Yield = 23.33% (FCF TTM 4.32b / Enterprise Value 18.52b)
FCF Margin = 2.22% (FCF TTM 4.32b / Revenue TTM 194.78b)
Net Margin = -3.43% (Net Income TTM -6.67b / Revenue TTM 194.78b)
Gross Margin = 12.24% ((Revenue TTM 194.78b - Cost of Revenue TTM 170.94b) / Revenue TTM)
Gross Margin QoQ = 15.18% (prev 16.38%)
Tobins Q-Ratio = 0.24 (Enterprise Value 18.52b / Total Assets 77.66b)
Interest Expense / Debt = 0.89% (Interest Expense 168.0m / Debt 18.78b)
Taxrate = 21.0% (US default 21%)
NOPAT = -5.07b (EBIT -6.42b * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.68 (Total Current Assets 35.99b / Total Current Liabilities 21.48b)
Debt / Equity = 0.94 (Debt 18.78b / totalStockholderEquity, last quarter 19.95b)
Debt / EBITDA = -0.17 (negative EBITDA) (Net Debt 889.0m / EBITDA -5.14b)
Debt / FCF = 0.21 (Net Debt 889.0m / FCF TTM 4.32b)
Total Stockholder Equity = 24.06b (last 4 quarters mean from totalStockholderEquity)
RoA = -8.34% (Net Income -6.67b / Total Assets 77.66b)
RoE = -27.74% (Net Income TTM -6.67b / Total Stockholder Equity 24.06b)
RoCE = -15.49% (EBIT -6.42b / Capital Employed (Equity 24.06b + L.T.Debt 17.35b))
RoIC = -12.13% (negative operating profit) (NOPAT -5.07b / Invested Capital 41.78b)
WACC = 3.70% (E(17.63b)/V(36.41b) * Re(6.89%) + D(18.78b)/V(36.41b) * Rd(0.89%) * (1-Tc(0.21)))
Discount Rate = 6.89% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -4.43%
[DCF] Terminal Value 80.82% ; FCFF base≈4.32b ; Y1≈2.84b ; Y5≈1.29b
[DCF] Fair Price = 82.05 (EV 41.24b - Net Debt 889.0m = Equity 40.35b / Shares 491.8m; r=5.90% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: -53.28 | EPS CAGR: -54.28% | SUE: 0.08 | # QB: 0
Revenue Correlation: 92.73 | Revenue CAGR: 8.06% | SUE: 2.05 | # QB: 12
EPS next Quarter (2026-06-30): EPS=1.11 | Chg7d=+0.026 | Chg30d=+0.037 | Revisions Net=+4 | Analysts=17
EPS current Year (2026-12-31): EPS=3.00 | Chg7d=+0.034 | Chg30d=+0.140 | Revisions Net=+2 | Growth EPS=+44.4% | Growth Revenue=-2.8%
EPS next Year (2027-12-31): EPS=4.15 | Chg7d=+0.024 | Chg30d=+0.125 | Revisions Net=+0 | Growth EPS=+38.4% | Growth Revenue=+1.0%
[Analyst] Revisions Ratio: +0.33 (8 Up / 4 Down within 30d for Next Quarter)
P/S = 0.1001
P/B = 0.8971
P/EG = 1.5233
Revenue TTM = 194.78b USD
EBIT TTM = -6.42b USD
EBITDA TTM = -5.14b USD
Long Term Debt = 17.35b USD (from longTermDebt, last quarter)
Short Term Debt = 196.0m USD (from shortTermDebt, last quarter)
Debt = 18.78b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 889.0m USD (from netDebt column, last quarter)
Enterprise Value = 18.52b USD (17.63b + Debt 18.78b - CCE 17.89b)
Interest Coverage Ratio = -9.46 (Ebit TTM -6.42b / Interest Expense TTM 678.0m)
EV/FCF = 4.29x (Enterprise Value 18.52b / FCF TTM 4.32b)
FCF Yield = 23.33% (FCF TTM 4.32b / Enterprise Value 18.52b)
FCF Margin = 2.22% (FCF TTM 4.32b / Revenue TTM 194.78b)
Net Margin = -3.43% (Net Income TTM -6.67b / Revenue TTM 194.78b)
Gross Margin = 12.24% ((Revenue TTM 194.78b - Cost of Revenue TTM 170.94b) / Revenue TTM)
Gross Margin QoQ = 15.18% (prev 16.38%)
Tobins Q-Ratio = 0.24 (Enterprise Value 18.52b / Total Assets 77.66b)
Interest Expense / Debt = 0.89% (Interest Expense 168.0m / Debt 18.78b)
Taxrate = 21.0% (US default 21%)
NOPAT = -5.07b (EBIT -6.42b * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.68 (Total Current Assets 35.99b / Total Current Liabilities 21.48b)
Debt / Equity = 0.94 (Debt 18.78b / totalStockholderEquity, last quarter 19.95b)
Debt / EBITDA = -0.17 (negative EBITDA) (Net Debt 889.0m / EBITDA -5.14b)
Debt / FCF = 0.21 (Net Debt 889.0m / FCF TTM 4.32b)
Total Stockholder Equity = 24.06b (last 4 quarters mean from totalStockholderEquity)
RoA = -8.34% (Net Income -6.67b / Total Assets 77.66b)
RoE = -27.74% (Net Income TTM -6.67b / Total Stockholder Equity 24.06b)
RoCE = -15.49% (EBIT -6.42b / Capital Employed (Equity 24.06b + L.T.Debt 17.35b))
RoIC = -12.13% (negative operating profit) (NOPAT -5.07b / Invested Capital 41.78b)
WACC = 3.70% (E(17.63b)/V(36.41b) * Re(6.89%) + D(18.78b)/V(36.41b) * Rd(0.89%) * (1-Tc(0.21)))
Discount Rate = 6.89% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -4.43%
[DCF] Terminal Value 80.82% ; FCFF base≈4.32b ; Y1≈2.84b ; Y5≈1.29b
[DCF] Fair Price = 82.05 (EV 41.24b - Net Debt 889.0m = Equity 40.35b / Shares 491.8m; r=5.90% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: -53.28 | EPS CAGR: -54.28% | SUE: 0.08 | # QB: 0
Revenue Correlation: 92.73 | Revenue CAGR: 8.06% | SUE: 2.05 | # QB: 12
EPS next Quarter (2026-06-30): EPS=1.11 | Chg7d=+0.026 | Chg30d=+0.037 | Revisions Net=+4 | Analysts=17
EPS current Year (2026-12-31): EPS=3.00 | Chg7d=+0.034 | Chg30d=+0.140 | Revisions Net=+2 | Growth EPS=+44.4% | Growth Revenue=-2.8%
EPS next Year (2027-12-31): EPS=4.15 | Chg7d=+0.024 | Chg30d=+0.125 | Revisions Net=+0 | Growth EPS=+38.4% | Growth Revenue=+1.0%
[Analyst] Revisions Ratio: +0.33 (8 Up / 4 Down within 30d for Next Quarter)